---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-019315"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2025-10-24T23:59:59+00:00"
generated_at: "2026-05-17T02:22:21.715504+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "low"
source: SEC EDGAR
---

# MAIA presents THIO-101 Phase 2 poster at AACR-NCI-EORTC conference on Oct 24, 2025

## Summary
- Poster on Ateganosine (THIO) + ICI in advanced NSCLC patients resistant to prior ICI and chemotherapy.
- Presented at AACR-NCI-EORTC Molecular Targets Conference in Boston.
- No specific efficacy or safety data disclosed in the 8-K filing.
- Company provided forward-looking statements caution.

## SEC filing metadata
- accession: 0001493152-25-019315
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2025-10-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000149315225019315/0001493152-25-019315-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000149315225019315/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-019315
- JSON: https://secwatch.observer/filing/0001493152-25-019315.json
- Plain text: https://secwatch.observer/filing/0001493152-25-019315.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.